More than a biological response.
Safer and faster treatment.

Faster healing and better quality of anchorage is the ultimate goal of an implant surface during osseointegration.

This increases the safety during the early healing phase and leads to a superior structural and functional connection between vital bone and the implant. The SLActive® surface is designed to provide a safer and faster treatment reducing the healing period from 6 – 8 weeks down to 3 – 4 weeks in all indications*.1 – 9

Enhance blood clot stabilization

The key in initiating the healing process is the blood clot formation on the implant surface. The hydrophilic and chemically active properties of SLActive® provide a larger accessible surface area for increased blood protein adsorption and fibrin network formation. Those are ideal conditions for blood clot formation and for the initiation of the healing process.1, 2, 3

Promotion of bone vascularization

Building a functional vascular system very early is critical for successful osseointegration. Blood vessel formation is an ongoing process in post-surgical healing. The SLActive® surface has shown a much higher stimulation of blood vessel growth compared to a hydrophobic surface.4, 5

Greater and faster bone formation

Building a greater bone foundation for implant treatment is crucial. The SLActive® surface supports faster bone maturation6. A higher degree of bone cell mineralization has been described in a preclinical study6 and confirmed by an in vitro study3. Moreover, in human histology the SLActive® healing process has been confirmed to be faster, as demonstrated by the greater bone-to-implant contact (BIC) after 2 weeks and the significantly greater BIC after 4 weeks.7

Reduce healing time from 6 - 8 weeks to 3 - 4 weeks

Most implant failures occur in the critical early healing phase between 2 – 4 weeks after implant placement8. SLActive® is designed to deliver better osseointegration properties by achieving secondary stability sooner than hydrophobic surfaces, thereby reduces the risks during the early healing time and eliminates the stability dip.9


1 Rupp F, Scheideler L, Olshanska N, de Wild M, Wieland M, Geis-Gerstorfer J. Enhancing surface free energy and hydrophilicity through chemical modification of microstructured titanium implant surfaces. Journal of Biomedical Materials Research A, 76(2):323-334, 2006. 2 De Wild M. Superhydrophilic SLActive® implants. Straumann document 151.52, 2005 3 Katharina Maniura. Laboratory for Materials – Biology Interactions Empa, St. Gallen, Switzerland Protein and blood adsorption on Ti and TiZr implants as a model for osseointegration. EAO 22nd Annual Scientific Meeting, October 17 – 19 2013, Dublin 4 Schwarz, F., et al., Bone regeneration in dehiscence-type defects at non-submerged and submerged chemically modified (SLActive®) and conventional SLA® titanium implants: an immunohistochemical study in dogs. J Clin.Periodontol. 35.1 (2008): 64–75. 5 Rausch-fan X, Qu Z, Wieland M, Matejka M, Schedle A. Differentiation and cytokine synthesis of human alveolar osteoblasts compared to osteoblast-like cells (MG63) in response to titanium surfaces. Dental Materials 2008 Jan;24(1):102-10. Epub 2007 Apr 27. 6 Schwarz F, Herten M, Sager M, Wieland M, Dard M, Becker J. Histological and immunohistochemical analysis of initial and early osseous integration at chemically modified and conventional SLA® titanium implants: Preliminary results of a pilot study in dogs. Clinical Oral Implants Research, 11(4): 481-488, 2007. 7 Lang, N.P., et al., Early osseointegration to hydrophilic and hydrophobic implant surfaces in humans. Clin Oral Implants.Res 22.4 (2011): 349–56. 8 Raghavendra S, Wood MC, Taylor TD. Int. J. Oral Maxillofac. Implants. 2005 May–Jun;20(3):425–31. 9 Oates TW, Valderrama P, Bischof M, Nedir R, Jones A, Simpson J, Toutenburg H, Cochran DL. Enhanced implant stability with a chemically modified SLA® surface: a randomized pilot study. Int. J. Oral Maxillofac. Implants. 2007;22(5):755–760.